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Peter R. Kowey, MD,yz Victoria M. Robinson, MBCHByThe world is full of obvious things, which
nobody by any chance ever observes.
— Sherlock Holmes (1)I t is fair to say that atrial ﬁbrillation (AF) hasreached epidemic proportions. With an agingpopulation and improved survival with concomi-
tant conditions, the prevalence of AF is predicted to
increase dramatically in the next several decades (2),
with profound implications for patients’ health, qual-
ity of life, and the global economy. It is therefore
important to monitor the epidemiology of this disease,
to identify novel and reversible risk factors and track
the impact of AF treatments at a population level.SEE PAGE 1000In this issue of the Journal, Vermond et al. (3)
present a large (n ¼ 8,256), prospective cohort study
evaluating the incidence, risk factors, and complica-
tions of AF in a contemporary population of patients,
28 to 75 years old, ostensibly free of AF at baseline.
The average length of follow up was 9.7  2.3 years.
The study had the advantage of a captured popula-
tion with excellent follow-up and conﬁrmable rhythm
diagnosis. The most important ﬁnding of this study is
that the incidence rate of AF (3.3/1,000 patient-years)
was comparable to previous epidemiological data,
despite a relatively young study population (mean
age: 49  13 years) with albuminuria. Earlier analyses
of AF incidence density over time indicated that it
remained stable between the mid-1990s to the mid-
2000s, but that AF prevalence has continued to rise*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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Dr. Kowey serves on the steering committee for the CABANA trial. Dr.
Robinson has reported that she has no relationships relevant to the
contents of this paper to disclose.(4). What are the most important contributors to this
important epidemiological development?
In their contemporary patient population, Vermond
et al. (3) identiﬁed obesity as a signiﬁcant risk factor
for incident AF, with a 45% increased risk for every
5 kg/m2 increase in body mass index. They propose
that obesity is likely a prominent factor contributing
to the signiﬁcant incidence of AF. A recent study by
Nystrom et al. (5) corroborated this ﬁnding but added
that being overweight (body mass index: 25.0 to
29.9 kg/m2), rather than obese, was a signiﬁcant risk
factor only when it was part of the metabolic syn-
drome. Animal studies suggest that obesity directly
contributes to the AF substrate by altering atrial
electrical and structural remodeling (6).
Obesity also could increase the risk of AF by its
association with risk factors that are not tradition-
ally included in epidemiological studies. Pericardial
fat has been identiﬁed as a risk factor for the
increased prevalence and severity of AF (4), perhaps
because it is metabolically active and produces in-
ﬂammatory cytokines (4). Similarly, patients with
obstructive sleep apnea (OSA) have roughly a 4-fold
increased risk of developing AF (4). It is not yet
clear whether OSA is a causal risk factor or part of a
larger risk proﬁle, but the ﬁnding that continuous
positive pressure ventilation reduces the recurrence
rates of AF in these patients suggests a possible
pathogenic role (7). Unfortunately, data on OSA or
pericardial fat were not available in the study by
Vermond et al. (3) and are not commonly reported
in the literature.
There is a ray of hope in the midst of the obesity
and AF epidemics. Studies have demonstrated that
physician-led weight loss programs can signiﬁcantly
reduce the number of AF episodes, as well as the
symptom burden and severity in obese patients with
AF (8,9). Such studies indicate that the medical
community will likely need to take a much more
active role in facilitating risk factor modiﬁcation to
slow the rising incidence of AF globally.
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1009Vermond et al. (3) showed that despite recent
advances in the treatment of AF and cardiovascular
disease, AF remains strongly associated with adverse
cardiovascular outcomes and mortality. Stroke, car-
diovascular disease, and heart failure remained the
most signiﬁcant complications of AF in this study.
A prevailing theory to explain why mortality and
complication rates of AF have remained static over
time is that we are not intervening early enough in
the course of the disease. This may partly explain
why large trials such as AFFIRM (Atrial Fibrillation
Follow-up Investigation of Rhythm Management) (10)
demonstrated no signiﬁcant difference in mortality
beneﬁt between rate and rhythm control strategies
in AF (11). In addition, the antiarrhythmic drugs
currently available for AF have limited efﬁcacy and
considerable side effects. Ongoing large-scale trials
such as the CABANA (Catheter Ablation Versus Anti-
arrhythmic Drug Therapy for Atrial Fibrillation) trial
(NCT00911508) will provide information on whether
catheter ablation is a better therapeutic choice than
antiarrhythmic drugs. The EAST (Early Treatment of
Atrial Fibrillation for Stroke Prevention Trial) will also
elucidate whether earlier rhythm control strategies
improve AF outcomes (NCT01288352).
We also suspect that we have not nudged the
needle with regard to outcomes because we treat AF
as a homogenous disease when in fact it has a diverse
pathogenesis. Until we have better insight into oper-
ative mechanisms in individual patients, it is unlikely
that any of the treatments we devise will alter the
inevitable outcome of this complex disease.
Another factor contributing to the static trends of
AF-related mortality and complications is compli-
ance. This includes patients adhering to treatment
regimens and physicians following recommended
evidence-based practice guidelines. It is a factor
rarely mentioned in the current literature. The
World Health Organization (12) reported that medi-
cation adherence in developed countries is only
50%, and this percentage is presumed to be worse in
developing countries. The World Health Organizationemphasized the importance of improving patient
adherence and claimed that this factor is likely to
have a greater impact on population health than any
advance in alternative or improved treatments (12).
Unfortunately, no data are available on the treatment
regimens or patient compliance levels in the study by
Vermond et al. (3). Using data from large registries is
an effective way of monitoring treatment trends over
time and has the advantage of being more widely
applicable to the general population. Traditional
observational studies such as that of Vermond et al.
(3) are limited by the restricted population in a single
center. In addition, the method of AF detection in this
study was inadequate. Periodic sampling of electro-
cardiograms grossly underestimates the burden of AF
compared with long-term monitoring (13).
In conclusion, we congratulate the authors on
producing a robust epidemiological study conﬁrming
the incidence, risk factors, and complications of AF
in a selected, young, and contemporary population
of patients. Their ﬁndings once again highlight the
importance of identifying novel and reversible risk
factors for AF, so that we can increase our efforts to
prevent this disease. Moreover, the continued risk of
AF-associated mortality and cardiovascular compli-
cations demonstrated in this study emphasizes the
need to optimize evidence-based treatment guide-
lines and to encourage physicians to implement
these guidelines where appropriate. We must not
lose sight of the fact that despite our best efforts to
modify reversible risk factors, AF will continue to
emerge in older adults as a result of aging-induced
ﬁbrosis. Nevertheless, initiatives to improve patient
adherence to long-term prevention and treatment
regimens may help to ease the signiﬁcant societal
burden of AF.
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